TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Grand Pharmaceutical Group Limited ( (HK:0512) ) has provided an announcement.
Grand Pharmaceutical Group Limited announced the first commercial prescription of its nasal spray product, OC-01, for treating dry eye disease in Mainland China. This product, which is the first of its kind globally, offers a new treatment option for dry eye patients by increasing tear secretion through a nasal spray, potentially improving patient compliance compared to traditional eye drops. The company views ophthalmology as a strategic development area and aims to strengthen its market position with innovative products and a robust marketing network.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company focused on the pharmaceutical industry, particularly in the field of ophthalmology. The company is dedicated to the innovation of ophthalmic drugs and has established a diverse product system aimed at treating conditions such as myopia, dry eye, pterygium, and other ophthalmic diseases. The company is committed to enhancing its market competitiveness and industry position through continuous research and development.
Average Trading Volume: 33,150,132
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.15B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.